HealthLinx Limited (ASX:HTX) has expanded its collaboration with the University of Liverpool to assess the utility of its proprietary biomarkers for other indications. The expanded collaboration will have the University of Liverpool provide HealthLinx with blood samples for specific diseases where HealthLinx will run its proprietary biomarkers across these samples to determine their potential for future pipelines.
"The opportunity to expand our collaboration with Liverpool presents the company with an excellent opportunity to identify additional diseases that we may target to develop new diagnostics similar to OvPlex™," says Nick Gatsios managing director of HealthLinx.
http://www.biotech-intelligence.com/html/html/pool_7/4aba1345a9c9d69d487af474ac8bb4bf.html
How We Rank